{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/prescribing-information/muscarinic-agents/","result":{"pageContext":{"chapter":{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents","depth":2,"htmlHeader":"<!-- begin field 8d3b4dd9-fbd8-45eb-b748-a6d7016bd965 --><h2>Muscarinic agents</h2><!-- end field 8d3b4dd9-fbd8-45eb-b748-a6d7016bd965 -->","summary":"","htmlStringContent":"<!-- begin item d75dbb2f-d5be-417d-89a7-a6d7016bd4e4 --><!-- end item d75dbb2f-d5be-417d-89a7-a6d7016bd4e4 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6973f571-e925-5efd-9282-7e404355d020","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field a6ce26d4-10af-4c82-8acb-a6f700eef0f6 --><h3>Which dose should be given?</h3><!-- end field a6ce26d4-10af-4c82-8acb-a6f700eef0f6 -->","summary":"","htmlStringContent":"<!-- begin item 53e471be-e5af-49a1-b25c-a6f700eeef83 --><!-- begin field f3684bab-bde8-4435-9262-a6f700eef0f6 --><p>Ipratropium bromide is a muscarinic agent that can be used to treat asthma in all age groups, with tiotropium licensed as an add-on therapy for adults who have experienced one or more severe asthma exacerbations in the past year. Both are delivered via pressurized metered dose inhalers. Doses are as follows:</p><ul><li><strong>Ipratropium bromide.</strong><ul><li>Adults and children aged 12 years and older — 20 to 40 micrograms 3 to 4 times daily.</li><li>Children aged 6 to 11 years — 20 to 40 micrograms 3 times daily.</li><li>Children aged 1 month to 5 years — 20 micrograms 3 times daily.</li></ul></li><li><strong>Tiotropium.</strong><ul><li>Adults — 5 micrograms once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field f3684bab-bde8-4435-9262-a6f700eef0f6 --><!-- end item 53e471be-e5af-49a1-b25c-a6f700eeef83 -->","subChapters":[]},{"id":"eda93651-2045-5c59-af2f-7972fed6b255","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1da2bb7e-d81b-4a52-8826-a6da01163926 --><h3>Contraindications and cautions</h3><!-- end field 1da2bb7e-d81b-4a52-8826-a6da01163926 -->","summary":"","htmlStringContent":"<!-- begin item d4647cc1-a535-464a-a4c0-a6da011636a1 --><!-- begin field db81a163-fc6f-45a6-83f3-a6da01163926 --><ul><li>Do not prescribe ipratropium bromide or tiotropium to people with a known hypersensitivity to atropine or its derivatives.</li><li>Prescribe ipratropium bromide and tiotropium with caution to people with:<ul><li>Narrow-angle glaucoma or a pre-disposition to narrow-angle glaucoma.</li><li>Urinary outflow tract obstruction (such as prostatic hyperplasia or bladder outflow obstruction). </li><li>Cystic fibrosis.</li></ul></li><li>Prescribe tiotropium with caution to people with:<ul><li>A history of myocardial infarction within the previous 6 months, any unstable or life-threatening cardiac arrhythmia, or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year, or hospitalisation due to heart failure (NYHA Class III or IV) within the past year.</li><li>Moderate to severe renal impairment (creatinine clearance ≤ 50 ml/min).<ul><li>Plasma concentration of tiotropium increases with decreasing renal function. Use in people with renal impairment only if the expected benefit outweighs the potential risk.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018c</a>]</p><!-- end field db81a163-fc6f-45a6-83f3-a6da01163926 --><!-- end item d4647cc1-a535-464a-a4c0-a6da011636a1 -->","subChapters":[]},{"id":"d4bab4e8-b4e6-5c43-8ba3-c7949a71f061","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 208a63b3-f42a-4533-bdaf-a6da01164d2d --><h3>Adverse effects</h3><!-- end field 208a63b3-f42a-4533-bdaf-a6da01164d2d -->","summary":"","htmlStringContent":"<!-- begin item 7d573498-98be-4fc6-a869-a6da01164ac3 --><!-- begin field 987ca17a-ee36-4338-a545-a6da01164d2d --><p><strong>Adverse effects of ipratropium bromide and tiotropium include:</strong></p><ul><li>Constipation.</li><li>Cough.</li><li>Diarrhoea. </li><li>Nausea</li><li>Dry mouth. </li><li>Gastro-intestinal motility disorder.</li><li>Headache.</li><li>Sinusitis.</li><li>Stomatitis.</li><li>Narrow angle glaucoma.<ul><li>Should the person develop eye pain or discomfort, blurred vision, visual halos, or coloured images in association with red eyes from conjunctival congestion and corneal oedema, treat with miotic drops and seek urgent specialist advice.</li><li>Ocular complications are more likely if the product comes into direct contact with the eyes. Instruct the person on the correct administration of their inhaler and warn against the accidental release of its contents into the eye.</li></ul></li></ul><p><strong>Other adverse effects of iptratropium include:</strong></p><ul><li>Laryngospasm</li><li>Pharyngeal oedema.</li><li>Vomiting.</li><li>Ocular accommodation disorder (rarely).</li></ul><p><strong>Other adverse effects of tiptropium include:</strong></p><ul><li>Gingivitis.</li><li>Glossitis.</li><li>Insomnia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 987ca17a-ee36-4338-a545-a6da01164d2d --><!-- end item 7d573498-98be-4fc6-a869-a6da01164ac3 -->","subChapters":[]},{"id":"138b0c62-ffd0-510f-8a86-8a27f03feede","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6379b02c-6b1a-42c6-bdeb-a6da01165fe1 --><h3>Drug interactions</h3><!-- end field 6379b02c-6b1a-42c6-bdeb-a6da01165fe1 -->","summary":"","htmlStringContent":"<!-- begin item 7e7e1d8b-c6d3-4acf-92e2-a6da01165d9d --><!-- begin field c6ba620a-35a2-4531-a7eb-a6da01165fe1 --><ul><li><strong>Beta-2 agonists and xanthines</strong> — may produce an additive bronchodilatory effect with ipratropium bromide.</li><li><strong>Other anticholinergic drugs</strong> — are not recommended to be co-administered with tiotropium bromide as the effects of this have not been studied.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 72, 2016</a>]</p><!-- end field c6ba620a-35a2-4531-a7eb-a6da01165fe1 --><!-- end item 7e7e1d8b-c6d3-4acf-92e2-a6da01165d9d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}